

48. (New) The method of claim ¹⁶~~17~~ wherein the human or animal has a disease or disorder selected from the group consisting of a bacterial infection, a fungal infection and a cancer.

19. (New) The method claim ¹⁷~~18~~, wherein the disease or disorder is a cancer.

20. (New) The method of claim ¹⁸~~19~~, wherein the cancer is selected from the group consisting of stomach cancer, lung cancer and lymphoma.

21. (New) The method of claim ¹⁶~~17~~, wherein the pharmaceutical composition comprises the modified cecropin A-magainin 2 of SEQ ID NO:2.

REMARKS

Claims 1-8 are canceled and new claims 10-21 are provided. Claims 10-21 more particularly set forth that which Applicants consider to be their invention. The replacement claims are respectfully urged to be fully supported by the specification and/or by cancelled claims 1-8.

For example, claims 10-11 and 12-13 are supported by the specification, e.g., from page 10, line 18 through page 11, line 3, which describes the nature of the preferred amino acid substitutions into the cecropin A-magainin peptide of SEQ ID NO:1, both generally and specifically. For instance, at page 10, lines 22-25, the substitutions into the Gly-Ile-Gle "hinge region" are defined. Reference to SEQ ID NO:1 confirms that Gly-Ile-Gle residues are found at residues numbered 9, 10 and 11. The remaining members of the peptide Markush group are set forth by the specification from page 10, line 26, through page 11, line 3.


Pharmaceutical compositions as recited by claim 12, et seq., are described, e.g., beginning at page 14, line 8, et seq. This same section of the specification is also urged to support methods of treating a human or animal in need thereof by detailing the various pharmaceutical

formulations. Turning to claim 16, et seq., methods of treatment for humans and in veterinary practice are noted, e.g., beginning at page 19, line 19, of the specification. Anti-bacterial, anti-fungal and anti-tumor cell activity is also illustrated by the several examples provided by the specification.

For all of these reasons, it is respectfully urged that no new matter has been added, and that the present application is in condition for examination and allowance, and early action to that end is respectfully solicited. If the Examiner has any questions regarding the amendments presented herein, it is requested that the Examiner contact the undersigned at the telephone number shown below.

No fee is believed to be owed for entry of the instant amendment, but if it is determined that a fee is due, any deficiency or overpayment concerning this document should be charged or credited to Deposit Account No. 50-0217.

Respectfully submitted,
ROBERTS & MERCANTI, L.L.P.

By: 
Laurence Manber
Reg. No. 35,597

ROBERTS & MERCANTI, L.L.P.
P.O. Box 3156
Newark, New Jersey 07103-0156
Phone: (973) 621-0660
Fax: (973) 621-0774